Research location
Cullman
Alabama, United States
Advertisement
Research activity in Cullman
Alabama, United StatesCureCurrent currently publishes aggregate city-level research activity for this location: 98 trials and 98 site observations.
The map is centered on registry-derived city coordinates. Circle size reflects published trial activity.
Below are current trials with one or more ClinicalTrials.gov site observations in this city. Results are paginated 50 per page, with recruiting studies shown first.
Trials with sites in Cullman
98 linked trials · page 1 of 2A Study to Learn About the Monthly Dosing Study Medicine Called Berobenatide in Adults With Breathing Problems During Sleep and Overweight or Obesity Who Use a Breathing Machine (PAP) (VESPER-OSA 1)NCT07823608 · 2026-09-17 · 1 site observation
RECRUITING
A Study to See How Safe and Effective Alirocumab is When Given Weekly to Adult Participants Who Have HypercholesterolemiaNCT07477704 · 2026-06-17 · 1 site observation
RECRUITING
A Study of Eloralintide (LY3841136) in Participants With Obstructive Sleep Apnea and Obesity or OverweightNCT07369011 · 2026-02-10 · 1 site observation
RECRUITING
Non-inferiority Study of Frexalimab Subcutaneous Administration Compared to Intravenous Administration in Adult Participants With Multiple SclerosisNCT07325292 · 2026-01-14 · 1 site observation
RECRUITING
A Study of Eloralintide (LY3841136) in Participants With Obesity or Overweight, and Type 2 DiabetesNCT07282600 · 2025-12-15 · 1 site observation
RECRUITING
A Study to Investigate the Efficacy and Safety of Tezepelumab in Adult Participants With Moderate to Very Severe COPD (D5241C00007)NCT06878261 · 2025-03-25 · 1 site observation
RECRUITING
A Study Evaluating the Real World Experience of Participants Treated With BRIUMVI® (Ublituximab-xiiy) for Relapsing Multiple Sclerosis (RMS)NCT06433752 · 2024-07-22 · 1 site observation
RECRUITING
A Study Evaluating the Efficacy of Budesonide, Glycopyrronium and Formoterol Fumarate Metered Dosed Inhaler on Cardiopulmonary Outcomes in Chronic Obstructive Pulmonary DiseaseNCT06283966 · 2024-02-21 · 1 site observation
RECRUITING
Study to Evaluate Safety, Efficacy and Pharmacokinetics (PK) of a Modified Regimen of UblituximabNCT05877963 · 2023-06-13 · 1 site observation
RECRUITING
A Study of Weekly Oral Dose of Ecnoglutide (VRB-101) for Weight Maintenance in Participants Who Have Obesity or Overweight With Weight-Related ComorbiditiesNCT07553299 · 2026-06-12 · 1 site observation
ACTIVE_NOT_RECRUITING
Efficacy and Safety of Ribupatide Administered Once Weekly in Participants Living With Obesity or Overweight and DiabetesNCT07284901 · 2026-01-12 · 1 site observation
ACTIVE_NOT_RECRUITING
Efficacy and Safety of Ribupatide in Participants Living With Obesity or Overweight With Weight-Related Comorbidities Who Do Not Have DiabetesNCT07284875 · 2025-12-18 · 1 site observation
ACTIVE_NOT_RECRUITING
A Study of Weekly Oral Ecnoglutide (VRB-101) in Participants Who Have Obesity or Overweight With Weight-Related ComorbiditiesNCT07281937 · 2025-11-25 · 1 site observation
COMPLETED
A Research Study to See How a Weekly Insulin, Insulin Icodec, Helps in Reducing the Blood Sugar Compared to Daily Insulin Glargine, Both in Combination With Insulin Aspart, in Adults With Type 1 DiabetesNCT07076199 · 2025-08-11 · 1 site observation
ACTIVE_NOT_RECRUITING
Efficacy and Safety of Petrelintide in Participants With Overweight or Obesity and Type 2 Diabetes (ZUPREME 2)NCT06926842 · 2025-04-22 · 1 site observation
COMPLETED
A Study of Obexelimab in Patients With Relapsing Multiple Sclerosis (MoonStone)NCT06564311 · 2024-08-26 · 1 site observation
ACTIVE_NOT_RECRUITING
Dose-Finding Study Evaluating Effect on Body Composition of Enobosarm in Patients Taking a GLP-1 for Chronic Weight MgmtNCT06282458 · 2024-04-29 · 1 site observation
COMPLETED
A Study to Investigate Long-term Safety and Tolerability of Tolebrutinib in Participants With Multiple Sclerosis.NCT06372145 · 2024-04-16 · 1 site observation
ACTIVE_NOT_RECRUITING
A Study to Test if Trevogrumab or Trevogrumab With Garetosmab When Taken With Semaglutide is Safe and How Well They Work in Adult Patients With Obesity for Weight Loss, Fat Loss, and Lean Mass PreservationNCT06299098 · 2024-03-13 · 1 site observation
ACTIVE_NOT_RECRUITING
Effect of Naltrexone Hydrochloride ER and Bupropion Hydrochloride ER Combination (Contrave®/Mysimba®) on Major Adverse Cardiovascular Events (MACE)NCT06098079 · 2024-01-03 · 1 site observation
ACTIVE_NOT_RECRUITING
Efficacy and Safety Studies of Frexalimab (SAR441344) in Adults With Relapsing Forms of Multiple SclerosisNCT06141473 · 2023-12-13 · 1 site observation
ACTIVE_NOT_RECRUITING
A Study of Retatrutide (LY3437943) in Participants With Type 2 Diabetes Mellitus Who Have Obesity or OverweightNCT05929079 · 2023-07-11 · 1 site observation
COMPLETED
Safety and Efficacy of Bimagrumab and Semaglutide in Adults Who Are Overweight or ObeseNCT05616013 · 2022-11-16 · 1 site observation
COMPLETED
CASCADE-LUNG: Cancer Screening Assay Using DELFI; A Clinical Validation Study in LungNCT05306288 · 2022-04-07 · 1 site observation
ACTIVE_NOT_RECRUITING
A Multicenter Study of Continued Current Therapy vs Transition to Ofatumumab After Neurofilament (NfL) ElevationNCT05090371 · 2022-03-02 · 1 site observation
ACTIVE_NOT_RECRUITING
Study Assessing the Long-term Effect of Dupilumab on Prevention of Lung Function Decline in Adult Patients With Uncontrolled Moderate to Severe AsthmaNCT05097287 · 2021-12-16 · 1 site observation
ACTIVE_NOT_RECRUITING
Evaluation of Safety, Tolerability and Preliminary Efficacy of EHP-101 in Relapsing Forms of Multiple SclerosisNCT04909502 · 2021-10-19 · 1 site observation
SUSPENDED
Study to Evaluate the Efficacy and Safety of Fenebrutinib Compared With Teriflunomide in Relapsing Multiple Sclerosis (RMS)NCT04586023 · 2021-03-24 · 1 site observation
ACTIVE_NOT_RECRUITING
A Study to Evaluate the Efficacy, Safety and Pharmacokinetics (PK) of a Higher Dose of Ocrelizumab in Adults With Relapsing Multiple Sclerosis (RMS)NCT04544436 · 2020-11-26 · 1 site observation
ACTIVE_NOT_RECRUITING
Assessment of ANK-700 in Patients With Relapsing Remitting Multiple SclerosisNCT04602390 · 2020-11-06 · 1 site observation
COMPLETED
Pivotal Study to Assess the Efficacy, Safety and Tolerability of Dupilumab in Patients With Moderate to Severe COPD With Type 2 InflammationNCT04456673 · 2020-07-06 · 1 site observation
COMPLETED
Study of Evobrutinib in Participants With RMS (evolutionRMS 2)NCT04338061 · 2020-07-02 · 1 site observation
TERMINATED
Relapsing Forms of Multiple Sclerosis (RMS) Study of Bruton's Tyrosine Kinase (BTK) Inhibitor Tolebrutinib (SAR442168) (GEMINI 2)NCT04410991 · 2020-06-11 · 1 site observation
COMPLETED
Study Describing Cognitive Processing Speed Changes in Relapsing Multiple Sclerosis Subjects Treated With Ozanimod (RPC-1063)NCT04140305 · 2020-01-16 · 1 site observation
TERMINATED
Long Term Safety and Efficacy Study of Tolebrutinib (SAR442168) in Participants With Relapsing Multiple SclerosisNCT03996291 · 2019-09-23 · 1 site observation
COMPLETED
A Study to Asses Efficacy, Safety and Tolerability of Monthly Long-acting IM Injection of GA Depot in Subjects With RMSNCT04121221 · 2019-09-19 · 1 site observation
COMPLETED
A Study of Suboptimally Controlled Participants Previously Taking Oral or Infusion DMDs for RMS (MASTER-2)NCT03933202 · 2019-07-22 · 1 site observation
COMPLETED
Dose-finding Study for SAR442168 in Relapsing Multiple SclerosisNCT03889639 · 2019-03-29 · 1 site observation
COMPLETED
Safety and Tolerability of Conversion From Oral, Injectable, or Infusion Disease Modifying Therapies to Dose-titrated Oral Siponimod (Mayzent) in Advancing RMS PatientsNCT03623243 · 2019-02-14 · 1 site observation
COMPLETED
Long-term Safety, Tolerability and Effectiveness Study of Ofatumumab in Patients With Relapsing MSNCT03650114 · 2018-12-28 · 1 site observation
ACTIVE_NOT_RECRUITING
A Study to Evaluate Efficacy, Safety, and Tolerability of EID of Natalizumab (BG00002) in Participants With RRMS Switching From Treatment With Natalizumab SID in Relation to Continued SID Treatment- Followed by Extension Study Comprising SC and IV Natalizumab AdministrationNCT03689972 · 2018-11-27 · 1 site observation
COMPLETED
A Safety and Efficacy Study of ADS-5102 in Patients With Multiple Sclerosis and Walking ImpairmentNCT03567057 · 2018-07-18 · 1 site observation
COMPLETED
Safety and Efficacy of ADS-5102 in Multiple Sclerosis Patients With Walking ImpairmentNCT03436199 · 2018-03-29 · 1 site observation
COMPLETED
Tele-Exercise and Multiple SclerosisNCT03117881 · 2018-01-08 · 1 site observation
COMPLETED
Efficacy and Safety of BIIB033 (Opicinumab) as an Add-on Therapy to Disease-Modifying Therapies (DMTs) in Relapsing Multiple Sclerosis (MS)NCT03222973 · 2017-11-15 · 1 site observation
TERMINATED
A Study of Immune Phenotype Biomarkers in Patients With Relapsing Multiple Sclerosis (RMS) After Treatment With 0.5mg FingolimodNCT03257358 · 2017-09-19 · 1 site observation
COMPLETED
The INSYTE (Management of Parkinson's Disease Psychosis in Actual Practice) StudyNCT03152292 · 2017-03-30 · 1 site observation
TERMINATED
A Tolerability Study of ALKS 8700 in Subjects With Relapsing Remitting Multiple Sclerosis (RRMS) EVOLVE-MS-2NCT03093324 · 2017-03-15 · 1 site observation
COMPLETED
Efficacy and Safety of Ofatumumab Compared to Teriflunomide in Patients With Relapsing Multiple Sclerosis.NCT02792231 · 2016-08-26 · 1 site observation
COMPLETED
A Study of Ocrelizumab in Participants With Relapsing Remitting Multiple Sclerosis (RRMS) Who Have Had a Suboptimal Response to an Adequate Course of Disease-Modifying Treatment (DMT)NCT02637856 · 2016-02-11 · 1 site observation
COMPLETED
Advertisement
Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.